Guardant Health, Inc. (GH) — SEC Filings

Latest SEC filings for Guardant Health, Inc. (GH), explained in plain English.

Sentiment Overview: 2 bullish, 2 bearish, 33 neutral, 2 mixed

Recent Filings (39)

• Guardant Health: Insider Roberto Mignone Files Form 4 — 4 · 2026-03-23T16:19:34-04:00 [neutral]
  This Form 4 filing from March 23, 2026, indicates a change in beneficial ownership for Guardant Health, Inc. (Issuer CIK: 0001576280). The filing lists Roberto
• 8-K Filing — 8-K · 2025-11-07T00:00:00.000Z [neutral]
• Guardant Health Revenue Jumps 38% on Shield Test Momentum, Losses Narrow — 10-Q · 2025-10-29T00:00:00.000Z [mixed] Risk: medium
  Guardant Health, Inc. (GH) reported a significant increase in revenue for the three months ended September 30, 2025, reaching $265.2 million, up from $191.5 mil
• Guardant Health Files 8-K — 8-K · 2025-09-24T00:00:00.000Z [neutral] Risk: low
  Guardant Health, Inc. filed an 8-K on September 24, 2025, to report information under Regulation FD. The filing does not contain specific financial transactions
• Guardant Health Announces Board and Executive Changes — 8-K · 2025-09-15T00:00:00.000Z [neutral] Risk: medium
  Guardant Health, Inc. announced on September 12, 2025, changes in its board of directors and executive compensation. The filing details the departure of certain
• Guardant Health's Q2 Revenue Jumps 20%, But Losses Widen to $150M — 10-Q · 2025-07-30T00:00:00.000Z [mixed] Risk: high
  Guardant Health, Inc. reported a net loss of $150.0 million for the three months ended June 30, 2025, a significant increase from the $120.0 million net loss in
• Guardant Health Reports on Shareholder Vote — 8-K · 2025-06-20T00:00:00.000Z [neutral] Risk: low
  Guardant Health, Inc. filed an 8-K on June 20, 2025, reporting on matters submitted to a vote of its security holders on June 18, 2025. The filing details the c
• 10-Q Filing — 10-Q · 2025-04-30T00:00:00.000Z [neutral]
• Guardant Health DEF 14A: Executive Comp & Governance — DEF 14A · 2025-04-29T00:00:00.000Z [neutral] Risk: medium
  Guardant Health, Inc. filed its DEF 14A on April 29, 2025, detailing executive compensation and corporate governance matters for the fiscal year ending December
• Guardant Health Files 8-K for Material Agreement — 8-K · 2025-04-09T00:00:00.000Z [neutral] Risk: medium
  Guardant Health, Inc. entered into a material definitive agreement on April 3, 2025. This filing also indicates the creation of a direct financial obligation or
• Guardant Health Files 2024 10-K — 10-K · 2025-02-20T00:00:00.000Z [neutral] Risk: medium
  Guardant Health, Inc. filed its 2024 10-K on February 20, 2025, reporting on its fiscal year ending December 31, 2024. The filing details the company's financia
• Guardant Health Files 8-K on Agreements and Equity Sales — 8-K · 2025-02-14T00:00:00.000Z [neutral] Risk: medium
  Guardant Health, Inc. filed an 8-K on February 14, 2025, reporting on several key events. These include entering into a material definitive agreement, creating
• Guardant Health Files 8-K: Material Agreement & Equity Sales — 8-K · 2025-02-07T00:00:00.000Z [neutral] Risk: medium
  On February 6, 2025, Guardant Health, Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities an
• Guardant Health Files 8-K on Financials — 8-K · 2025-01-13T00:00:00.000Z [neutral] Risk: low
  Guardant Health, Inc. filed an 8-K on January 13, 2025, reporting on its results of operations and financial condition. The filing also included Regulation FD d
• SC 13G Filing — SC 13G · 2024-11-13T00:00:00.000Z [neutral]
• SC 13G Filing — SC 13G · 2024-11-08T00:00:00.000Z [neutral]
• Guardant Health Files Q3 2024 10-Q — 10-Q · 2024-11-06T00:00:00.000Z [neutral] Risk: medium
  Guardant Health, Inc. filed its 10-Q for the period ending September 30, 2024. The filing covers the third quarter of 2024 and provides financial updates. Key d
• Guardant Health Appoints New Director, Updates Executive Compensation — 8-K · 2024-10-24T00:00:00.000Z [neutral] Risk: low
  Guardant Health, Inc. announced on October 21, 2024, changes in its officer and director positions. The company elected a new director, Dr. Amirali Z. Hirji, an
• SC 13G/A Filing — SC 13G/A · 2024-10-07T00:00:00.000Z [neutral]
• Guardant Health Enters Material Definitive Agreement — 8-K · 2024-08-23T00:00:00.000Z [neutral] Risk: medium
  Guardant Health, Inc. announced on August 23, 2024, that it has entered into a material definitive agreement. The filing does not disclose specific details of t
• Guardant Health Files Q2 2024 10-Q — 10-Q · 2024-08-07T00:00:00.000Z [neutral] Risk: medium
  Guardant Health, Inc. filed its 10-Q for the period ending June 30, 2024. The filing details financial performance and operational updates for the second quarte
• Guardant Health Files 8-K Regulatory Update — 8-K · 2024-07-29T00:00:00.000Z [neutral] Risk: low
  Guardant Health, Inc. filed an 8-K on July 29, 2024, to report other events and financial statements. The filing does not contain specific details about new agr
• Guardant Health Announces Board and Executive Compensation Changes — 8-K · 2024-07-18T00:00:00.000Z [neutral] Risk: low
  Guardant Health, Inc. announced on July 17, 2024, changes in its board of directors and executive compensation arrangements. Specifically, the company reported
• SC 13G/A Filing — SC 13G/A · 2024-07-05T00:00:00.000Z [neutral]
• Guardant Health Reports on Shareholder Vote Matters — 8-K · 2024-06-14T00:00:00.000Z [neutral] Risk: low
  Guardant Health, Inc. filed an 8-K on June 14, 2024, reporting on matters submitted to a vote of security holders on June 12, 2024. The filing details the compa
• Guardant Health Appoints New CEO, Adds Directors — 8-K · 2024-05-31T00:00:00.000Z [neutral] Risk: medium
  Guardant Health, Inc. announced on May 24, 2024, a change in its board of directors. Specifically, Dr. Amirali Talasaz has been appointed as the new Chief Execu
• Verily to Acquire Guardant Health for $5.1B — 8-K · 2024-05-24T00:00:00.000Z [bullish] Risk: medium
  Guardant Health, Inc. announced on May 23, 2024, that it has entered into a definitive agreement to be acquired by Verily Life Sciences, a subsidiary of Alphabe
• Guardant Health Files Q1 2024 10-Q — 10-Q · 2024-05-09T00:00:00.000Z [neutral] Risk: medium
  Guardant Health, Inc. filed its 10-Q for the period ending March 31, 2024. The filing details financial performance and operational updates for the first quarte
• Guardant Health Files DEF 14A for 2023 — DEF 14A · 2024-04-25T00:00:00.000Z [neutral] Risk: low
  Guardant Health, Inc. filed a DEF 14A on April 25, 2024, for the fiscal year ending December 31, 2023. The filing details executive compensation and other corpo
• SC 13G Filing — SC 13G · 2024-04-12T00:00:00.000Z [neutral]
• Guardant Health Announces Executive Changes and Board Appointments — 8-K · 2024-03-22T00:00:00.000Z [neutral] Risk: medium
  Guardant Health, Inc. announced on March 18, 2024, the departure of its Chief Medical Officer, Dr. Amirali Talasaz, effective March 15, 2024. The company also r
• Guardant Health Files 2023 10-K, Details Financials — 10-K · 2024-02-22T00:00:00.000Z [neutral] Risk: medium
  Guardant Health, Inc. filed its 10-K on February 22, 2024, for the fiscal year ending December 31, 2023. The company, a medical laboratory service provider base
• SC 13G/A Filing — SC 13G/A · 2024-02-13T00:00:00.000Z [neutral]
• Capital International Investors Cuts Guardant Health Stake to 3.8% — SC 13G/A · 2024-02-09T00:00:00.000Z [bearish] Risk: medium
  Capital International Investors, a Delaware-based investment firm, filed an amended SC 13G/A on February 9, 2024, disclosing its ownership in Guardant Health, I
• FMR LLC & Abigail Johnson Trim Guardant Health Stake to 4.504% — SC 13G/A · 2024-02-09T00:00:00.000Z [bearish] Risk: medium
  FMR LLC, a major investment firm, and its principal owner, Abigail P. Johnson, have updated their ownership stake in Guardant Health, Inc. (GH) through an SC 13
• Guardant Health Amends Executive Compensation Arrangements — 8-K · 2024-02-01T00:00:00.000Z [neutral]
  Guardant Health, Inc. filed an 8-K on February 1, 2024, reporting an event on January 26, 2024, related to changes in its executive compensation arrangements. T
• Baillie Gifford Discloses 9.89% Stake in Guardant Health — SC 13G · 2024-01-29T00:00:00.000Z [bullish]
  Baillie Gifford & Co, a prominent investment management firm, reported on January 29, 2024, that as of December 29, 2023, they beneficially own 10,240,637 share
• BlackRock Amends Guardant Health Stake, Signals Continued Confidence — SC 13G/A · 2024-01-25T00:00:00.000Z [neutral]
  BlackRock Inc. filed an amended SC 13G/A on January 25, 2024, indicating its ownership of Guardant Health, Inc. (GH) common stock as of December 31, 2023. This
• Guardant Health 8-K Signals Upcoming Financial Disclosure — 8-K · 2024-01-08T00:00:00.000Z [neutral]
  Guardant Health, Inc. filed an 8-K on January 8, 2024, indicating that it will be disclosing information related to its 'Results of Operations and Financial Con